News Archives - Med CPD

SURMOUNT-4 RCT and the Tirzepatide Breakthrough

New drug Tirzepatide shows promise for long-term weight loss and managing obesity-related health issues. Learn how it works, its benefits for overweight/obese patients, and the future of this exciting therapy.

Are Australian Sexual & Reproductive Health Rights Threatened?

Australia leads in SRHR progress, but vigilance is key. Learn about policy wins, ongoing challenges & the crucial role of GPs in safeguarding these rights.

Australia’s First National Health and Climate Strategy

Australia takes a ground breaking step toward climate action with its first National Health and Climate Strategy. This ambitious plan tackles both climate's impact on health and the health system's carbon footprint, paving the way for a healthier, more sustainable..

The NHMRC makes vaping position heard

The NHMRC raises alarms about rising e-cigarette use, particularly among youth, and highlights the dangers despite misconceptions of safety. Explore research, social media influence, and clinical implications for healthcare professionals.

Australian First: Learner Quality Scores in Medical Professional Development

With a burgeoning array of education providers and an ever-growing list of learning opportunities, the challenge for medical professionals to identify quality education has become increasingly complex.

Could Hepatitis C be eliminated by 2030?

The eradication of hepatitis C as a public health concern by 2030 faces significant challenges, as evidenced by recent findings from a joint report by the Burnet Institute and the Kirby Institute.

Gut bacteria the missing link in Insulin Resistance

Insulin resistance is a key factor in the development of metabolic syndrome and type 2 diabetes.

The first roll-out of the New Medicare model

The landscape of general practice in Australia is set for a pivotal change from November 1, 2023, with the introduction of new Medicare Benefits Schedule (MBS) bulk billing items that substantially increase incentive payments for practitioners.

Shingrix to replace Zostavax on the National Immunisation Program

In a significant leap forward, Australia's National Immunisation Program (NIP) is set to introduce the recombinant zoster vaccine (RZV), known commercially as Shingrix, replacing the less potent Zostavax.